

Dr. Joseph Frank Pizzolato

EXPERTISE: Lower Gastrointestinal Cancers

- Colon
- Rectal
- Anal
- Carcinoid

PROFESSIONAL EDUCATION & TRAINING:

Hematology & Oncology Fellowship: Memorial Sloan Kettering Cancer Center; Weill Medical College of Cornell University, New York, NY

Residencies: Internal Medicine, Columbia-Presbyterian Hospital, New York, NY

Medical School: MD, Mount Sinai School of Medicine, New York, NY

Education: BA Biochemistry, Minor Italian; *magna cum laude* New York University, NY

POSTDOCTORAL EDUCATION:

Memorial Sloan-Kettering Cancer Center Human Subjects Research Training Course

Memorial Sloan-Kettering Cancer Center Clinical Research Methodology Course

Rockefeller University Tri-Institutional Ethics in Research Course

Memorial Sloan-Kettering Cancer Center Biostatistics Course

New York Blood Bank Course

BOARD CERTIFICATIONS:

American Board of Internal Medicine: Internal Medicine

American Board of Internal Medicine: Medical Oncology

American Board of Internal Medicine: Hematology

CURRENT POSITIONS:

Attending Physician in Hematology and Oncology, Co-Director Gastrointestinal Malignancies; The Mount Sinai Comprehensive Cancer Center, Miami, FL

PROFESSIONAL MEMBERSHIPS & ACCOMPLISHMENTS:

American Society of Clinical Oncology, Member

FLASCO Speaker: "Colon Cancer : Why do we do what we do" 2009

Alpha Omega Alpha

PUBLICATIONS:

1. Soares HP, Herna S, Macintyre J, Merchan JR, Levi J, Sleeman D, Ribeiro A, Koniaris L, **Pizzolato J**, Rocha-Lima CM "Does age affect treatment outcome in pancreatic adenocarcinoma? A joint cancer database analysis", 2009 Gastrointestinal Cancers Symposium A253
2. **Pizzolato JF**, Minsky BD, Guillen J, Shia J, Gonen M, Saltz LB, "Neoadjuvant Combined Chemoradiation for uT3/4 rectal cancer: A retrospective comparison of Infusional versus Bolus Fluorouraci", Proceedings of ASCO 2005 A248
3. **Pizzolato JF**, Baum MS, Steingart RM, Gonen M, Minsky BD, Saltz LB, "Cardiac toxicity of 5FU: Does prophylactic telemetry monitoring of patients at increased risk for cardiac toxicity improve safety? A 10-year experience", Proceedings of ASCO 2004, A8107
4. **Pizzolato JF**, Saltz LB, "Irinotecan in the Treatment of Pancreatic Cancer", Expert Review of Anticancer Therapy, 3(5), 2003.
5. **Pizzolato JF**, Saltz LB, "The camptothecins", Lancet, 2003, 361(9376):2235-42.
6. Tang HY, Zhao K, **Pizzolato JF**, Fonarev M, Langer JC, and Manfredi JJ, "Constitutive expression of the cyclic dependent kinase inhibitor p21 is transcriptionally regulated by the tumor suppressor protein p53", J Biol Chem, 1998, 273, 29156-63.
7. **Pizzolato JF**, Sharma S, Maki R, Krug M, Hammershaimb L, Pluda J, "Phase I study of Medi-522, an $\alpha V\beta 3$ integrin inhibitor, in patients with irinotecan-refractory colorectal cancer", Proceedings of ASCO 2003, A983.
8. **Pizzolato J**, Greenberg D, Streeter G, Manfredi J, Arkin S, Benjamin D, and Tendler CL, "Mutant p53 in AIDS-Lymphoma Cell Lines is Associated With Resistance to Chemotherapy and Radiation-Induced Apoptosis", Blood, 1995, Vol 86 No 10 A2943.